CLINICAL_TRIALS
trial_result
· 2024-05-20
Clinical Trial Update: A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) [Phase 3]
Summary
Phase 3 TRAILBLAZER-ALZ 2 trial update for donanemab in early Alzheimer's disease with results posted in May 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Alzheimer Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-05-20